• Working with

    passion, integrity,
    & true innovation

  • Developing

    novel, first-in-class therapeutics

  • Targeting

    major unmet medical needs

  • Changing

    the approach to
    treating cancer

Imetelstat

First-in-class, first-in-clinic,
telomerase inhibitor

 

Telomerase

Learn about our innovative approach to developing a treatment for cancer

 

Divestiture of
Stem Cell Assets

Click here for further information

 

Geron News

4.2.2014

Geron to Present at the Needham Healthcare Conference

Read More

3.20.2014

Geron Reports Myelofibrosis IST Placed on Partial Clinical Hold

Read More

3.12.2014

Geron Announces IND Clinical Hold Affecting Clinical Trials of Imetelstat in Essential Thrombocythemia and Multiple Myeloma

Read More

 

Events

5.20.2014

Geron 2014 Annual Meeting of Stockholders

Learn More

Vote Your Shares

4.8.2014

Geron at the Needham Healthcare Conference

Listen to Webcast

Download Slides

3.12.2014

Geron Conference Call

Listen to Webcast